Indoco Remedies Ltd. delivered a remarkable financial turnaround in Q1FY27, posting a consolidated net profit of ₹64.99 crore compared to a net loss of ₹35.79 crore in the corresponding quarter last year. According to reports from Business Standard, this represents a complete reversal of the company's financial position and demonstrates significant operational improvements. The latest figures show the company's ability to achieve sustained profitability after previous quarterly challenges. However, the profitability surge was largely non-operational, driven by an exceptional gain of ₹97.34 crore recognized from the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. Without this one-time item, the company incurred a pre-tax loss of ₹412 lakh, highlighting that core operational challenges persist despite the bottom-line improvement.
The pharmaceutical company's revenue from operations increased 8.43% year-on-year to ₹466.22 crore, up from ₹430.86 crore in Q1FY26, as reported by Business Standard. This revenue growth provided a solid foundation for the company's improved profitability. Domestic sales reached ₹312 crore and international sales stood at ₹155 crore. On a standalone basis, revenue from operations grew 5.8% year-on-year to ₹408 crore, with domestic sales contributing ₹228 crore and exports accounting for ₹180 crore. However, total expenses remained high at ₹417 crore, including employee benefits of ₹91 crore, keeping operational profitability under pressure.
The company's EBITDA margin expanded significantly to 8.7% compared with 3.8% in the year-ago quarter, representing more than a doubling of profitability margins. According to Business Standard, this margin expansion indicates improved operational efficiency and cost management during the quarter. The substantial improvement in EBITDA margins demonstrates the company's enhanced ability to convert revenue into profit, with the latest figures showing operating profit margin (OPM) at 8.7% compared to 3.8% in the previous year. The EBITDA rose to ₹40.8 crore from ₹16.7 crore year-on-year, reflecting improved operational leverage despite core operational challenges. The profit before tax reached ₹77.72 crore compared with a pre-tax loss of ₹36.66 crore in Q1FY26.
Despite the strong earnings performance, Indoco Remedies shares fell 5.89% to ₹233.15 on the BSE, as reported by Business Standard. The stock decline occurred even after the company announced its improved quarterly results, highlighting the market's cautious approach to the company's turnaround story. However, the stock has gained more than 6% so far in 2026, indicating positive long-term investor sentiment despite short-term market volatility. The latest market reaction suggests continued investor confidence in the company's turnaround story despite recent price movements. However, the financial results reveal a stark divergence between operational performance and reported profitability, with core operations continuing to generate losses and statutory auditors flagging going concern uncertainty at subsidiary FPP Holding LLC, which continues to have a negative net worth of ₹3,822.60 lakh despite earning a net profit of ₹300.89 lakh in the quarter.
